EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Evaluating the evidence for genotype‐informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review

Dhrita Khatri iD, Ben Felmingham, Claire Moore, Smaro Lazaraki, Tayla Stenta, Lane Collier, David A Elliott iD, David Metz, Rachel Conyers

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16203 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Dhrita Khatri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Graft Rejection, Immunosuppressive Agents, Organ Transplantation, Tacrolimus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Future Fund-Genomics Health Future Mission, Children's Hospital Foundation, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus, a calcineurin inhibitor, is a highly effective immunosuppressant used in solid organ transplantation (SOT). However, it is characterized by a narrow therapeutic range and high inter‐patient variability in pharmacokinetics. Standard weight‐based dosing followed by empiric dose titration is suboptimal in controlling drug concentrations, increasing risk of rejection or toxicity, particularly in the initial months post transplantation. This review explores the potential of combined pre‐transplant genotyping and pharmacokinetic (PK) modelling to improve tacrolimus dosing in paediatric SOT recipients. A systematic search of Medline, Embase and Cochrane databases identified studies published between March 2013 and March 2023 that investigated genotype‐ and PK model‐informed tacrolimus dosing in children post‐SOT. The Newcastle‐Ottawa Scale assessed study quality. Seven studies encompassing paediatric kidney, heart, liver and lung transplants reported using genotype and model‐informed dosing. A combination of clinical and genetic factors significantly impacts tacrolimus clearance and thus initial dose recommendation. Body size, transplant organ and co‐medications were consistently important, while either time post‐transplant or haematocrit emerged in some studies. Several models were identified, however, with limitations evident in some and with absence of evidence for their effectiveness in optimizing initial and subsequent dosing. This review highlights the development of PK models in paediatric SOT that integrate genotype and clinical covariates to personalize early tacrolimus dosing. While promising, prospective studies are needed to validate and confirm their effectiveness in improving time to therapeutic concentrations and reducing under‐ or overexposure. This approach has the potential to optimize tacrolimus therapy in paediatric SOT, thereby improving outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionImmunosuppressive AgentsOrgan TransplantationTacrolimusChildHumansBayes TheoremCalcineurin InhibitorsDose-Response Relationship, DrugGenotypeModels, Biological

Stichwörter der Autor:innen

Bayesian estimationpaediatricspharmacogenomicspharmacokineticsprecision medicinetacrolimustransplantation

Substanzen

Calcineurin InhibitorsImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Melbourne, VIC, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
  • Health Sciences Library, Royal Melbourne Hospital, Melbourne Health, Australia.
  • Department of Nephrology, The Royal Children's Hospital, Melbourne, VIC, Australia.
  • Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Department of Paediatrics, Monash University, Melbourne, VIC, Australia.

ORCID-Profile: Dhrita Khatri, David A Elliott

Förderung

  • Medical Research Future Fund-Genomics Health Future Mission
  • Children's Hospital Foundation
  • Novo Nordisk Foundation
  • National Health and Medical Research Council
  • Victorian Government
  • Melbourne University
  • Novo Nordisk Fonden
  • State Government of Victoria

Zitieren

APA

Khatri, D., Felmingham, B., Moore, C., Lazaraki, S., Stenta, T., Collier, L., Elliott, D. A., Metz, D., & Conyers, R. (2024). Evaluating the evidence for genotype‐informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16203

Vancouver

Khatri D, Felmingham B, Moore C, Lazaraki S, Stenta T, Collier L, et al. Evaluating the evidence for genotype‐informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16203

BibTeX
@article{Khatri2024,
  author = {Khatri, Dhrita and Felmingham, Ben and Moore, Claire and Lazaraki, Smaro and Stenta, Tayla and Collier, Lane and Elliott, David A and Metz, David and Conyers, Rachel},
  title = {Evaluating the evidence for genotype‐informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16203}
}
Kostenlos starten →